Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE J GREEN

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1073581344
CMS profile
93488
Location
ROCKVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$334,930.89

335 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 7; records 251–300 of 335 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE J GREEN

NPI 1073581344 · CMS profile ID 93488

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

ROCKVILLE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 7; records 251–300 of 335 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073581344?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE J GREEN, NPI 1073581344, CMS profile ID 93488. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 335 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073581344?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). LAWRENCE J GREEN, NPI 1073581344, CMS profile ID 93488. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 335 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073581344?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
LAWRENCE J GREEN, NPI 1073581344, CMS profile ID 93488, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 335 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073581344?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

335 matching records · $334,930.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 335 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 335.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $764.4603/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648122247 CMS
AbbVie, Inc. $14.8003/07/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648122249 CMS
Janssen Scientific Affairs, LLC $24.9003/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657594261 CMS
Mayne Pharma Inc. $32.0003/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705497121 CMS
AbbVie, Inc. $4.9703/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648122191 CMS
Sun Pharmaceutical Industries Inc. $20.7503/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634685 CMS
Sun Pharmaceutical Industries Inc. $2,800.0003/01/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634705 CMS
Sun Pharmaceutical Industries Inc. $45.3203/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634707 CMS
Sun Pharmaceutical Industries Inc. $50.3003/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634709 CMS
Celgene Corporation $112.7502/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672840739 CMS
Celgene Corporation $3,000.0002/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672855495 CMS
Celgene Corporation $41.7602/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673012709 CMS
AbbVie, Inc. $3,500.0002/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648122159 CMS
Sun Pharmaceutical Industries Inc. $32.0002/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634771 CMS
Sun Pharmaceutical Industries Inc. $50.0002/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634773 CMS
Sun Pharmaceutical Industries Inc. $4,400.0002/23/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634775 CMS
Sun Pharmaceutical Industries Inc. $507.3502/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634777 CMS
Sun Pharmaceutical Industries Inc. $251.6402/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634779 CMS
Sun Pharmaceutical Industries Inc. $148.6802/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634781 CMS
Mayne Pharma Inc. $12.7502/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705497119 CMS
Sun Pharmaceutical Industries Inc. $20.0002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634765 CMS
Sun Pharmaceutical Industries Inc. $7.0002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634767 CMS
Sun Pharmaceutical Industries Inc. $16.0002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634769 CMS
Celgene Corporation $2,180.0002/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672834969 CMS
Lilly USA, LLC $19.1102/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657964795 CMS
AbbVie, Inc. $97.1202/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648122161 CMS
Celgene Corporation $24.7602/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672836871 CMS
Celgene Corporation $3,000.0002/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672837955 CMS
Celgene Corporation $18.2202/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672837961 CMS
Novartis Pharmaceuticals Corporation $173.6502/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659644593 CMS
Novartis Pharmaceuticals Corporation $500.6002/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659644595 CMS
Novartis Pharmaceuticals Corporation $3,600.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659644597 CMS
Novartis Pharmaceuticals Corporation $118.0602/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659644599 CMS
Novartis Pharmaceuticals Corporation $607.7602/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659644601 CMS
Celgene Corporation $48.7202/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672826353 CMS
Celgene Corporation $23.6302/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672831721 CMS
Celgene Corporation $3,410.0002/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672836915 CMS
Celgene Corporation $3,000.0002/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672827953 CMS
Celgene Corporation $1,424.4002/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672830113 CMS
Celgene Corporation $19.8902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672836347 CMS
Celgene Corporation $4,230.0002/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672843399 CMS
Celgene Corporation $4,230.0002/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672844523 CMS
Celgene Corporation $125.0002/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672847991 CMS
Celgene Corporation $16.1802/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673012411 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $21.0702/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684580571 CMS
Celgene Corporation $3,410.0001/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672826215 CMS
Celgene Corporation $62.6401/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672834231 CMS
Celgene Corporation $124.8901/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673011807 CMS
AbbVie, Inc. $2,500.0001/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648122239 CMS
Celgene Corporation $6.8101/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672726565 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $334,930.89 335
PY2020 $99,370.64 105
PY2021 $60,427.36 100
PY2022 $158,235.76 199
PY2023 $164,514.08 250
PY2024 $181,759.05 271
PY2025 $76,062.15 150

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $353,141.84 19
PY2025 Principal investigator $245,659.85 51
PY2024 Recipient $157,289.82 16
PY2024 Principal investigator $271,649.25 236
PY2023 Recipient $30,468.66 7
PY2023 Principal investigator $425,127.35 164
PY2022 Principal investigator $173,260.95 30
PY2021 Principal investigator $129,918.23 9
PY2020 Recipient $894.30 1
PY2020 Principal investigator $222,767.68 11
PY2019 Recipient $341,663.44 6
PY2019 Principal investigator $467,150.17 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,324.00 12/19/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499529
Recipient Takeda Pharmaceuticals U.S.A., Inc. $57,386.65 12/19/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262962
Principal investigator 1 PFIZER INC. $2,505.03 12/16/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730880
Principal investigator 1 Incyte Corporation $1,462.00 12/04/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499525
Recipient Takeda Pharmaceuticals U.S.A., Inc. $2,204.07 12/01/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262958
Recipient Takeda Pharmaceuticals U.S.A., Inc. $9,539.04 12/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262960
Principal investigator 1 Incyte Corporation $4,668.00 11/25/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499521
Principal investigator 1 PFIZER INC. $2,505.03 11/25/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730424
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,935.71 11/19/2025 Non-covered Recipient Entity
AESTHETICS SKIN CARE DERMATOLOGIC SURGERY
A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190314155
Principal investigator 1 Eli Lilly and Company $34,954.00 11/04/2025 Non-covered Recipient Entity
LAWRENCE J GREEN MD LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187886376
Principal investigator 1 PFIZER INC. $1,746.03 11/04/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730420
Recipient Takeda Pharmaceuticals U.S.A., Inc. $20,762.18 11/03/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262956
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Aesthetic And Dermatology Center
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235999205
Principal investigator 1 Incyte Corporation $2,186.00 10/29/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499509
Principal investigator 1 Janssen Research & Development, LLC $2,934.00 10/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175229968
Principal investigator 1 Janssen Research & Development, LLC $3,696.00 10/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175230191
Principal investigator 1 Incyte Corporation $1,462.00 10/23/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499514
Recipient Takeda Pharmaceuticals U.S.A., Inc. $12,097.20 10/22/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262954
Principal investigator 1 Incyte Corporation $1,617.00 10/09/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499518
Principal investigator 1 PFIZER INC. $3,159.42 10/03/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228741492
Recipient Takeda Pharmaceuticals U.S.A., Inc. $22,735.12 09/26/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262952
Principal investigator 1 Incyte Corporation $2,186.00 09/23/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499506
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11,595.36 09/03/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262950
Principal investigator 1 Incyte Corporation $1,700.00 08/21/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499493
Principal investigator 1 Incyte Corporation $376.00 08/14/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499501
Principal investigator 1 PFIZER INC. $1,746.03 08/14/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228789098
Principal investigator 1 Incyte Corporation $1,617.00 08/07/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499497
Principal investigator 1 PFIZER INC. $1,746.03 08/05/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228786447
Recipient Takeda Pharmaceuticals U.S.A., Inc. $15,555.34 08/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262946
Recipient Takeda Pharmaceuticals U.S.A., Inc. $13,287.20 08/01/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262948
Principal investigator 1 PFIZER INC. $1,413.39 06/26/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228719975
Recipient Takeda Pharmaceuticals U.S.A., Inc. $14,082.75 06/25/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262944
Principal investigator 1 Incyte Corporation $1,324.00 06/12/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499488
Recipient Takeda Pharmaceuticals U.S.A., Inc. $35,142.06 06/04/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262942
Principal investigator 1 Incyte Corporation $376.00 05/22/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499484
Recipient Takeda Pharmaceuticals U.S.A., Inc. $3,742.20 05/21/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262940
Principal investigator 1 Janssen Research & Development, LLC $7,490.00 05/15/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175230045
Principal investigator 1 PFIZER INC. $2,826.78 05/14/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228783704
Principal investigator 1 Incyte Corporation $3,510.00 05/08/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499481
Recipient Takeda Pharmaceuticals U.S.A., Inc. $11,909.70 05/07/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262938
Principal investigator 1 PFIZER INC. $2,550.90 05/06/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228765184
Principal investigator 1 Janssen Research & Development, LLC $3,745.00 04/28/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175230028
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,167.29 04/17/2025 Non-covered Recipient Entity
Lawrence J Green Md Llc
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235996235
Recipient Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 04/16/2025 Covered Recipient Physician TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262936
Recipient Takeda Pharmaceuticals U.S.A., Inc. $14,953.29 04/04/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262932
Recipient Takeda Pharmaceuticals U.S.A., Inc. $14,879.08 04/04/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262934
Principal investigator 1 Incyte Corporation $752.00 04/01/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499477
Principal investigator 1 Eli Lilly and Company $1,414.11 03/25/2025 Non-covered Recipient Entity
LAWRENCE J GREEN MD LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187887214
Principal investigator 1 Janssen Research & Development, LLC $7,619.00 03/21/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175230074
Principal investigator 1 Eli Lilly and Company $32,488.32 03/19/2025 Non-covered Recipient Entity
LAWRENCE J GREEN MD LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 1187885364
Principal investigator 1 PFIZER INC. $1,334.19 03/14/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228788805
Principal investigator 1 Incyte Corporation $2,186.00 03/04/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499473
Principal investigator 1 PFIZER INC. $8,889.87 03/04/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781662
Principal investigator 1 Janssen Research & Development, LLC $7,748.00 03/03/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175230021
Recipient Takeda Pharmaceuticals U.S.A., Inc. $16,241.61 03/03/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262930
Recipient Takeda Pharmaceuticals U.S.A., Inc. $41,684.00 02/26/2025 Covered Recipient Physician TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223262928
Principal investigator 1 Incyte Corporation $39,780.00 02/11/2025 Non-covered Recipient Entity
AESTHETIC AND DERMATOLOGY CENTER
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240499533
Principal investigator 1 Janssen Research & Development, LLC $254.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175229897
Principal investigator 1 Janssen Research & Development, LLC $4,143.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175229905
Principal investigator 1 Janssen Research & Development, LLC $205.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175229947
Principal investigator 1 Janssen Research & Development, LLC $574.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175229978
Principal investigator 1 Janssen Research & Development, LLC $270.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175229993
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175230037
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175230107
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 01/29/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175230116
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,600.00 01/28/2025 Non-covered Recipient Entity
Regents of the University of California, UCSD Depository -S
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1248163794
Principal investigator 1 PFIZER INC. $5,731.44 01/24/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228800153
Recipient Takeda Pharmaceuticals U.S.A., Inc. $25,344.99 01/22/2025 Covered Recipient Physician A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223262926
Principal investigator 1 Janssen Research & Development, LLC $3,874.00 01/16/2025 Non-covered Recipient Entity
Lawrence J Green MD Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175229941
Principal investigator 1 PFIZER INC. $2,272.99 01/15/2025 Non-covered Recipient Entity
Lawrence J Green MD LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228799957